相关临床试验
13
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
进行中（未招募）
1
7.7%
已完成
8
61.5%
招募中
1
7.7%
终止
2
15.4%
撤回
1
7.7%
暂无批准数据
- The European Medicines Agency's CHMP issued a positive opinion recommending approval of mavorixafor (XOLREMDI®) for WHIM syndrome treatment in patients aged 12 years and older. - The recommendation is based on results from the pivotal Phase 3 4WHIM trial, which demonstrated significant improvements in neutrophil and lymphocyte counts and a 40% reduction in infection scores. - Final approval decision from the European Commission is expected in Q2 2026, potentially making this the first authorized treatment for WHIM syndrome in Europe. - Norgine will commercialize the therapy across Europe, Australia and New Zealand following regulatory approval under a licensing agreement with X4 Pharmaceuticals.
- X4 Pharmaceuticals raised $135 million through a public offering to fund Phase 3 development of mavorixafor, following the previous approval of Xolremdi for WHIM Syndrome in 2024. - The company's stock surged 22.06% despite significant financial challenges, including an EBIT margin of -282.2% and negative operating cash flow of $29.9 million. - X4 Pharmaceuticals maintains an 83% gross margin on $2.56 million in revenue but faces operational inefficiencies and high debt-to-equity ratio of 19.65. - The capital raise demonstrates investor confidence in the company's rare disease drug development capabilities while addressing liquidity constraints for late-stage clinical trials.
- X4 Pharmaceuticals completed an upsized $85 million private placement, increasing from the originally announced $60 million offering to accommodate an investor with pre-existing investment rights. - The financing was led by Coastlands Capital with participation from existing investors including Bain Capital Life Sciences, NEA, and other leading life science investors. - Proceeds will fund continued development of mavorixafor toward potential additional approval in chronic neutropenia and support commercialization of WHIM syndrome treatment. - The company is currently conducting a global Phase 3 clinical trial (4WARD) evaluating mavorixafor in patients with certain chronic neutropenic disorders.
- X4 Pharmaceuticals announced a $60 million private placement financing led by Coastlands Capital, Bain Capital Life Sciences, and New Enterprise Associates to support continued development of mavorixafor. - The company simultaneously appointed a new leadership team including Dr. Adam Craig as Executive Chairman, John Volpone as President, and David Kirske as Chief Financial Officer, all formerly of CTI BioPharma. - The financing will fund continued development toward potential approval of mavorixafor in chronic neutropenia, in addition to commercialization of XOLREMDI for WHIM syndrome. - X4's CXCR4 antagonist mavorixafor is currently undergoing a global Phase 3 clinical trial (4WARD) in chronic neutropenic disorders while being marketed as XOLREMDI in the U.S.
• The FDA has approved novel therapies for Duchenne Muscular Dystrophy, including ITF Therapeutics' Duvyzat (givinostat), which targets histone deacetylases to potentially slow muscle deterioration. • Breakthrough gene therapy Lenmeldy received approval for Metachromatic Leukodystrophy, offering the first targeted treatment option with significant survival benefits for pediatric patients. • Multiple rare diseases saw first-ever treatments, including Xolremdi for WHIM syndrome, dual approvals for Niemann-Pick Disease Type C, and Ctexli for Cerebrotendinous Xanthomatosis.
- X4 Pharmaceuticals' Marketing Authorization Application (MAA) for mavorixafor to treat WHIM syndrome is under EMA review, potentially the first EU-approved drug for the condition. - Mavorixafor's MAA is supported by Phase 3 trial results, showing reduced infection rates and severity in WHIM syndrome patients with a good safety profile. - Norgine and X4 Pharmaceuticals have an exclusive licensing agreement to commercialize mavorixafor in Europe, Australia, and New Zealand upon regulatory approval. - Mavorixafor, already approved in the U.S. as XOLREMDI, is a CXCR4 antagonist, aiming to increase circulating neutrophils and lymphocytes in WHIM syndrome patients.
- The FDA approved Madrigal's Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), addressing a significant unmet need in liver disease. - X4 Pharmaceuticals' Xolremdi gained approval as the first targeted therapy for WHIM syndrome, a rare immunodeficiency, marking a milestone for the company. - Day One Biopharmaceuticals' Ojemda secured approval for BRAF-altered pediatric low-grade glioma, offering a new treatment option for this common childhood brain tumor. - Geron Corporation's Rytelo, a telomerase inhibitor, received FDA approval for lower- to intermediate-risk myelodysplastic syndromes (MDS), after 34 years in business. - ImmunityBio's Anktiva, a novel IL-15 superagonist, was approved for non-muscle invasive bladder cancer, providing a new therapeutic approach for BCG-unresponsive patients.
- X4 Pharmaceuticals announced positive Phase 2 results for mavorixafor in chronic neutropenia (CN), demonstrating increased neutrophil counts. - The Phase 3 4WARD trial of mavorixafor in CN is progressing, with full enrollment expected by mid-2025. - XOLREMDI® (mavorixafor) U.S. launch for WHIM syndrome is underway, with EMA submission anticipated in early 2025. - Market research indicates high awareness and increased screening for WHIM syndrome, supporting XOLREMDI adoption.
- X4 Pharmaceuticals reported positive Phase 2 clinical data for mavorixafor in chronic neutropenia (CN), showing increased neutrophil counts. - The Phase 2 study demonstrated that once-daily oral mavorixafor was well-tolerated and effectively elevated participants' neutrophil counts. - X4's pivotal Phase 3 trial of mavorixafor in CN is progressing as planned, with full enrollment expected by mid-2025. - The U.S. launch of XOLREMDI® (mavorixafor) for WHIM syndrome is underway, and EMA submission is anticipated by early 2025.
- The FDA has approved XOLREMDI (mavorixafor) for patients 12 years and older with WHIM syndrome, marking the first targeted therapy for this rare immunodeficiency. - XOLREMDI, a CXCR4 antagonist, demonstrated significant improvements in absolute neutrophil and lymphocyte counts in the pivotal 4WHIM Phase 3 clinical trial. - The approval was based on data showing increased time above threshold for neutrophil and lymphocyte counts, along with a reduction in infection rates compared to placebo. - X4 Pharmaceuticals has launched X4Connect to support patients in accessing XOLREMDI, which will be available through PANTHERx Rare specialty pharmacy.
